Evidence map›Paper›PMID 34763665›Full record

ArticleBasic and clinical andrology2021

D-Chiro-Inositol improves testosterone levels in older hypogonadal men with low-normal testosterone: a pilot study.

Maurizio Nordio, Philip Kumanov, Alfonsina Chiefari, Giulia Puliani

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Basic and clinical andrology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04708249 (D-chiroinositol Administration for Testosterone Level Improvement in Hypogonadal Males), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04708249 nacompletednot on this map

D-chiroinositol Administration for Testosterone Level Improvement in Hypogonadal Males

TypeinterventionalSponsorLo.Li.Pharma s.r.lRan2021 to 2021Enrolled10ConditionsMale Hypogonadism, Sexual DysfunctionArmsD-chiroinositol
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Inositols: From Established Knowledge to Novel Approaches.International journal of molecular sciences · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Maurizio NordioThe Expert Group on Inositol in Basic and Clinical Research (EGOI), Rome, Italy. maurizionordio1@gmail.com.
Philip KumanovMedical Faculty, University Hospital of Endocrinology and Gerontology Ivan Penchev, Sofia, Bulgaria.
Alfonsina ChiefariOncological Endocrinology Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Giulia PulianiOncological Endocrinology Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Istituti di Ricovero e Cura a Carattere Scientifico · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSeveral recent journal articles report that D-chiro-inositol (DCI), primarily known as insulin second messenger, influences steroidogenesis. In particular, new evidence is arising on DCI ability to regulate aromatase expression and testosterone biosynthesis. In this regard, DCI administration could represent a good therapeutic opportunity in case of reduced levels of testosterone. Older men generally have lower testosterone concentrations than younger men, and recent randomized controlled trials have examined whether testosterone treatment might improve health outcomes in this age group. There is limited information about the safety of testosterone replacement therapy in these men, hence DCI could represent an interesting alternative for future trials. Therefore, this study aims to evaluate the effect of DCI treatment on testosterone levels in older male patient.

resultsTen older men with basal low testosterone levels were enrolled in this study. Patients took 600 mg of DCI, two-times per day, for 30 days. We evaluated hormonal and glycaemic parameters, weight, waist circumference, and Body-Mass Index at baseline (T0) and after 30 days (T1). Finally, all patients also filled in the standardized International Index of Erectile Function questionnaire and performed the Handgrip test at T0 and T1. Men receiving DCI showed increased androgen and reduced oestrogen concentrations, and improved glycaemic profiles. DCI was also associated with reduced weight, Body-Mass Index, waist circumference, and improved grip strength and self-reported sexual function. All these effects led to the improvement of sexual function and physical strength.

conclusionsIn this pilot study, DCI treatment improved the levels of testosterone and androstenedione at the expense of oestrogens in elder men with low basal levels of these hormones without adverse effects.

trial registrationClinicaltrials.gov: D-chiroinositol Administration in Hypogonadal Males, NCT04708249.

Indexed as

AromataseD-chiro-inositolFunctional hypogonadismInositolLate-onset hypogonadismMale ageingSexual dysfunctionTestosterone

Identifiers

PMID34763665
PMCPMC8588714
OpenAlexW3213949092

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.